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Abstract

Author Manuscript

Background and Purpose—Because robotic devices record the kinematics and kinetics of
human movements with high resolution, we hypothesized that robotic measures collected
longitudinally in patients after stroke would bear a significant relationship to standard clinical
outcome measures and, therefore, might provide superior biomarkers.
Methods—In patients with moderate-to-severe acute ischemic stroke, we used clinical scales and
robotic devices to measure arm movement 7, 14, 21, 30, and 90 days after the event at 2 clinical
sites. The robots are interactive devices that measure speed, position, and force so that calculated
kinematic and kinetic parameters could be compared with clinical assessments.
Results—Among 208 patients, robotic measures predicted well the clinical measures (crossvalidated R2 of modified Rankin scale=0.60; National Institutes of Health Stroke Scale=0.63;
Fugl-Meyer=0.73; Motor Power=0.75). When suitably scaled and combined by an artificial neural
network, the robotic measures demonstrated greater sensitivity in measuring the recovery of
patients from day 7 to day 90 (increased standardized effect=1.47).
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Conclusions—These results demonstrate that robotic measures of motor performance will more
than adequately capture outcome, and the altered effect size will reduce the required sample size.
Reducing sample size will likely improve study efficiency.
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Stroke is the leading cause of permanent disability in the United States.1 A combination of
an aging, stroke-prone population, improved neurological and medical care, and limitation
of treatments for acute stroke to intravenous thrombolysis or various endovascular
approaches2,3 has heightened the urgency for new and improved clinical trials.4 Trials of
neuroprotectants impose narrow treatment windows and make patient accession difficult and
time sensitive.5 Despite the establishment of networks of treatment centers, to be adequately
powered given the variability of outcome measures, clinical studies in stroke require large
sample sizes. The current successful treatment trials for stroke required 600 to 850
patients.2,3 Effect size and group number are partially determined by measurement
variability that, in turn, results from the disparate nature and extent of initial clinical deficits
and from reliance on multiple raters using scalar assessment tools, despite rigorous quality
control procedures.6 Furthermore, extensive training of raters and centralization of outcome
assessments reduce this variability; this partial solution carries its own costs.7 Thus, clinical
research in stroke would be aided by a reliable, repeatable, and speedy assessment of
continuous measures of impairment and its change during recovery. Such measurements
would also yield valuable, objective information for an emerging archive on motor behavior
after a stroke and the effect of different treatment on recovery. Interactive robotic
technology can perform these measurements. This powerful toolbox has also been used as a
training device with demonstrated significant benefits for poststroke motor recovery of the
upper but not the lower extremities.1,7–13
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Here, we describe a robotic assessment of 208 patients who were also evaluated with 4 wellknown clinical instruments (National Institutes of Health Stroke Scale [NIHSS], modified
Rankin scale [mRS], Fugl-Meyer [FM], and Motor Power [MP]). We tested whether robotassisted measurement of kinematic and kinetic (RMK2) predicted the clinical scales with
sufficient accuracy to serve as their surrogates and whether it is possible to design a more
sensitive RMK2-based end point to measure motor recovery and thus reduce the number of
subjects required to power future clinical trials.

Methods
Study Population

Author Manuscript

Patients with stroke (baseline NIHSS 7–20 recorded within 7 days of stroke onset) were
enrolled and exposed to a battery of standard clinical assessments, including the NIHSS, the
mRS, the FM, and the MP assessments. Each patient was also evaluated with the
commercial version of the MIT-Manus robot14 (Interactive Motion Technologies,
Watertown, MA) but did not receive any robotic therapy. Both the affected (paretic) and
unaffected limbs of patients were evaluated 7, 14, 21, 30, and 90 days after stroke onset. We
enrolled 208 patients at 2 sites (146 patients at Burke Rehabilitation Center, White Plains,
NY, and 62 at the Western Infirmary, Glasgow, Scotland, United Kingdom). To minimize
inter-rater variability on the clinical scales, all the patients were assessed by the same set of
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highly trained clinicians at each site. These patients were divided into 2 complementary
populations: (1) those with complete data sets for days 7 and 90 after stroke onset (hereafter
referred to as completers; n=87), and (2) those with some missing data on day 7 or 90
(referred to as noncompleters; n=121). Because there was no obvious advantage to patients
with stroke to participate in the study (it did not include any incentives such as robotic
therapy), many elected not to participate/return for all evaluations. In addition, to test the
sensitivity of robot-assisted surrogate marker against historical data, we selected a subset of
patients with stroke with a comparable degree of stroke severity as measured at day 7
NIHSS from the Virtual International Stroke Trials Archive (VISTA).15,16 In brief, based on
the frequency distribution of day 7 NIHSS from our study population, ranging from 0 to 24,
≈14 subjects were randomly chosen from the VISTA registry at the same clinical level
measured at day 7 for each one of our study patients.

Author Manuscript

Robot-Assisted Measurement of Kinematics and Kinetics
The RMK2 assessment consists of a series of visually guided and visually evoked
unconstrained reaching and circle-drawing movements and attempts to move against
resistance that a patient with stroke completes in 30 minutes.17 From these movements, the
metrics include deviation from a straight line, aim, average speed, peak speed, and duration
of movement while attempting to reach toward different targets. Three additional parameters
characterizing the smoothness of movement are calculated: mean divided by the peak speed,
mean magnitude of jerk normalized by the peak speed (best for discrete movements), and
root mean square of jerk normalized by the duration of the movement (best for rhythmic
movements). These unconstrained reaching movements are decomposed into submovements
to produce 6 additional kinematic metrics (number, duration, overlap, peak, interval, and
skewness of submovements).18

Author Manuscript

The circle-drawing task yields a metric that captures the coordination of arm movements.19
The kinematic set is completed with 3 additional kinetic parameters that measure the
strength of the shoulder and the ability of a patient to move against resistance or to hold
against an externally applied force, leading to a total of 35 measurements for each patient
(the parameter that measures shoulder strength has a ceiling effect and is measured only on
the impaired side).17 All parameters were linearly normalized between 0 and 1.
Model Generation

Author Manuscript

Given the large number of robot measures and possible combinations of measures, we built
a model that identified the optimal set of robot metrics to correlate with clinical outcome or
predicted clinical outcome. To minimize the effect of magnitude on the selection of
parameters, we normalized the parameters via z scoring. We used a standard approach to
build nonlinear models of the clinical scales with 3-layer artificial neural networks using
logistic functions for the hidden and output layers.20,21 The models were derived
independently for each clinical scale and were trained to predict the clinical scores of a
given patient on a given day from the respective RMK2 metrics using the completer
population as a training set. To minimize overfitting, subsets of relevant RMK2 metrics
were first identified using a feature selection algorithm.22,23 Once the relevant features were
identified, ensemble models comprising 10 neural network predictors were constructed
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using the same network topology and training parameters but initialized with a different
random number seed. The predictions of these 10 models were averaged to produce an
ensemble prediction.24 All models were cross-validated using the standard jackknife
approach that divided the training data into 10 disjoint subsets containing 10% of the
patterns each, systematically removing each subset from the training set, building a model
with the remaining patterns, and predicting the clinical scores of the removed patterns using
the optimized network parameters. The resulting predictions were compared with the
original clinical scores to determine their degree of agreement (R2CV). This process was
repeated 10× to obtain more robust cross-validation statistics. Finally, the best models
identified by cross-validation were validated on the noncompleters, who formed an
independent validation set.
Maximizing Effect Size With Novel Composites

Author Manuscript

We further tested whether the sensitivity of the clinical end points could be improved by
using a novel RMK2-based composite optimized for effect size. Effect size is a reliable
indicator of the ability of a scale to detect changes. It was assessed using Cohen’s d for
paired observations, defined as the mean divided by the SD of the day 7 to day 90 changes
over all the completers. Because optimizing nonlinear composites does not lead to a unique
solution (ill-posed mathematical problem), we restricted ourselves to using an algorithm
constructed by identifying among the preselected RMK2 metrics the feature that yielded the
maximum effect size and then adding 1 feature at a time until all preselected RMK2 metrics
were included.

Results
Author Manuscript

Descriptive Statistics
Descriptive statistics by clinical site and completion status are provided in Tables 1 and 2. In
this noninterventional observational study, no statistically significant difference in baseline
severity was seen between the completer and noncompleter populations.
Correlation Analysis

Author Manuscript

The correlation structure of the RMK2 data set is illustrated in Figure 1. The nonlinear map
was constructed using stochastic proximity embedding so as to preserve as much as possible
the correlation distances among features, defined as dij=1−abs(Rij), where Rij is the Pearson
correlation coefficient between the ith and jth features.25,26 The 4 clinical scales (red) show
a substantial degree of correlation to each other versus the majority of the RMK2
parameters, with FM and MP exhibiting a high level of correlation (R=0.933), as previously
demonstrated.6,17 Furthermore, for our patients, the RMK2 parameters on the affected side
(blue) are more correlated to the clinical scales than those on the nonaffected side (green).
Prediction of Clinical Scales
Figure 2 shows the asymptotic behavior with respect to the number of robot-derived
features. It is apparent that the robot-derived models for the FM and MP display comparable
predictive power; furthermore, they are better predictors than those for NIHSS and mRS.
The models retain much of their predictive power on the noncompleters as illustrated by the
Stroke. Author manuscript; available in PMC 2015 December 23.

Krebs et al.

Page 5

Author Manuscript

dotted lines in Figure 2. These are patients who were not used by the model during training
and represent an independent validation set. The weights and biases of the best model for
each clinical scale are summarized in Table I of the online-only Data Supplement.
Maximizing Effect Size

Author Manuscript

Based on the frequency distribution of day 7 NIHSS scores from our study population,
ranging from 0 to 24, we matched historical subjects from the VISTA database. This was
done using simple random sampling to provide the same proportion of patients within each
NIHSS point. This randomly selected group of 2937 patients had a day 7 mean NIHSS score
of 5.7±4.1 that improved by 2.1±3.1 points to day 90, giving a standardized effect size of
0.67 for the changes from day 7 to day 90 in completers. Figure 3 shows the average effect
size for the training and validation sets as a function of the number of robot-derived features
included in the composite (using a similar cross-validation procedure to the one described
earlier) and the historical value for NIHSS effect size.

Discussion
Limitations on Measurement Tools

Author Manuscript

The choice of primary outcome measure must be responsive to the targeted intervention to
reflect a clinically meaningful change. Therefore, clinical evaluations must allow
measurement of performance across multiple levels of function that correspond to
components of the International Classification of Functioning and Disability, namely, body
functions (specifically, movement abilities), activities, and participation. We selected the
FM assessment27,28 and the Medical Research Council MP29,30 to assess motor impairment
(International Classification of Functioning and Disability body function) and the
NIHSS31,32 and the mRS33,34 to assess clinician-based measures of ability and activity,
respectively (used in standard pharmacological interventions). Because of the practical
limitation of the 1-hour span to measure both clinical and RMK2 scales, we did not include
any additional assessment of functional use for the upper limb nor any patient-based
assessment of activity (International Classification of Functioning and Disability activity
level). Certainly, every scale has weaknesses as outlined by the ESO (European Stroke
Organization) Outcomes Working Party35 and potential for different forms of biases.
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The RMK2 also has limitations: it has a floor effect in that subjects must be able to
comprehend and follow basic instructions and partially move their impaired limb through a
visually evoked and visually guided task in a gravity-compensated environment. In an effort
to evaluate hemiplegic patients, we also included the evaluation of the so-called unaffected
arm. We will evaluate the effectiveness of the approach of including the unaffected arm in a
follow-up subgroup analysis including only patients with severe deficits.
Predicting Clinical Scales and Nonlinear Model
Here, we developed nonlinear models as predictors of the clinical scales. These nonlinear
models are markedly better than our past efforts using multilinear regression models for
chronic stroke,17 in which we used principal component analysis for feature selection before
model building. Here, we used the Ant algorithm for feature selection and artificial neural
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networks.22 The observed differences in predictive power between these different models
could be because of several factors, including the type and number of patients used in the 2
studies, the use of neural networks as opposed to multilinear regression, and the use of a
more elaborate feature selection algorithm. A direct comparison between these different
models revealed that most of the present gains stem from the use of nonlinear modeling.
RMK2 and Smaller Clinical Trials
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Similar to the individual items of the clinical scales, the individual RMK2 features are not as
sensitive individually (data not shown). However, optimized RMK2 composites with only 4
features increased the effect size compared with the clinical scales by as much as 107% for
the training and 83% for the validation set. This result cannot be attributed to motor learning
because we demonstrated the stability of the RMK2 measurements on both people with
chronic stroke and age-matched controls. An increase of 83% in effect size compared with
the validated set would result in a 70% reduction in the number of patients required to
achieve the typical 80% statistical power in a clinical trial. This potential reduction of the
sample size is even larger compared with the training set.
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One must take these results with the appropriate caveats. The population enrolled in this
study was highly selected, with a day 7 mean NIHSS score of 5.7±4.1. Clearly, any gains
that increased statistical power will need to be balanced against lower enrollment rates
imposed by the selection criteria and against potential failure to complete follow-up or to
comply with the RMK2 measurements. Furthermore, some of the apparent advantages of
RMK2 may arise from the opportunity to repeat measurements and to use the mean of
several. The same might be true if we use ordinal analysis, central adjudication by multiple
raters, and global testing procedures that combine complementary scales across clinical
domains and across time. Finally, in the current pool of completers, the NIHSS achieved a
much larger effect size than historical data (VISTA). This larger effect size was because of a
larger improvement among our completers with comparable variability. The pool of 2937
patients selected in the VISTA registry to match the distribution of our pool of 208 patients
at day 7 had an improvement of 2.1±3.1 by day 90, whereas our completers had an
improvement of 3.7±3.3. One might consider this difference with the appropriate caveats,
particularly considering that the historical patient data were treated at a different time and in
different institutions, and so there is inevitable bias.
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Despite robotics limited penetration to date in the poststroke neurorehabilitation arena (eg,
only 200 InMotion Arm robots were produced to date), taken together, our data suggest that
robotic measurements may enable early decision making in clinical testing, reduce required
sample sizes, and offer a more reliable method to track longitudinal change in patients
affected by stroke than using current clinical scales. Furthermore, this study marks a novel
beginning for the technology-based measurement of outcomes. It represents a proof of
principle, with other robotic and wearable devices potentially affording even further
efficiencies.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
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Stochastic proximity embedding map of the correlation distances of the clinical and RMK2
parameters for the completers cohort. The map was derived by computing the pairwise
Pearson correlation coefficients (R) for all pairs of features, converting them to correlation
distances (1−abs(R)), and embedding the resulting matrix into 2 dimensions in such a way
that the distances of the points on the map approximate as closely as possible the correlation
distances of the respective features. The clinical parameters are displayed as circles, the
RMK2 parameters on the affected side as diamonds, and the RMK2 parameters on the
unaffected side as squares. The map also shows distinct clusters of correlated variables that
are preserved on both the affected and unaffected sides (outlined by dark continuous and
light dashed ellipses, respectively). Aff indicates affected or paretic limb; FM, Fugl-Meyer;
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MP, Motor Power; MR, modified Rankin scale; M/P, the smoothness metric calculated from
the mean and peak movement speed; and NIH, National Institutes of Health.
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Figure 2.
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Cross-validated R2 of the best models derived from the completers (solid lines) and
validated with the noncompleters (dashed lines) for each of the 4 clinical scales using 2, 4, 6,
8, 10, 12, and 14 robot-derived RMK2 features. The figure shows the ability of the robotderived RMK2 models with increasing features to predict the clinical scales. The model
performance exhibits an asymptotic behavior with respect to the number of RMK2 features,
reaching the point of diminishing returns at ≈8 features for all 4 clinical scales. Note that the
small variance in the prediction of the trained data as shown by the small whiskers, which
for the most part, is not visible in the figure. FM indicates Fugl-Meyer; MP, Motor Power;
and NIH, National Institutes of Health.
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Figure 3.
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Optimization of effect size for robot-derived RMK2 metrics. The horizontal lines show the
day 7 to day 90 effect size for comparable patients of the historical Virtual International
Stroke Trials Archive (VISTA) data for the National Institutes of Health Stroke Scale
(NIHSS), as well the effect sizes for the NIHSS, Fugl-Meyer (FM), and Motor Power (MP)
assessment scales for our completers cohort. The figure also shows the performance of the
robot-derived RMK2 composites optimized for effect size for the trained (solid lines) and
cross-validated sets (dashed lines). Note the increase of >20% in cross-validated effect size
for the RMK2 composites compared with the clinical scales with 4 features for this study
(and >70% over the historical data).
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Demographics and Descriptive Statistics
Characteristic

Burke (n=146)

Sex, male

Western Infirmary (n=62)

49%

55%

74.4 (12.84)

67.27 (14.35)

Lesion side, right hemisphere

54%

58%

Handedness, right

88%

84%

Age, y

Ethnicity (white, Hispanic, Asian, black)

70%, 9.5%, 2%, 18.5%

100%

6.9 (4.8)

3.9 (3.2)

FM day 7 (/66)

35.9 (21.0)

51.2 (20.2)

MP day 7 (/70)

38.4 (19.8)

62.5 (15.2)

NIHSS day 7 (/42)

NIHSS day 90 (/42)

Author Manuscript

2.4 (2.7)

2.3 (2.0)

FM day 90 (/66)

51.5 (19.0)

58.6 (17.5)

MP day 90 (/70)

53.9 (16.8)

65.4 (12.4)

mRS day 90 (/5)

3.2 (1.1)

1.8 (1.1)

Values represent the percentage or mean (SD). FM indicates Fugl-Meyer; MP, Motor Power; mRS, modified Rankin scale; and NIHSS, National
Institutes of Health Stroke Scale.
/ indicates what is the maximum score in that particular scale.
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Table 2

Author Manuscript

Training and Validation Data Sets
Characteristic
Sex, male
Age, y
Lesion side, right hemisphere

Completers (n=87)

Noncompleters (n=121)

52%

51%

69.7 (13.5)

75.7 (13.0)

51%

56%

5.6 (4.3)

6.5 (4.9)

FM day 7 (/66)

40.3 (21.7)

38.5 (21.9)

MP day 7 (/70)

45.5 (20.1)

39.4 (21.7)

NIHSS day 7 (/42)

Values represent the percentage or mean (SD). FM indicates Fugl-Meyer; MP, Motor Power; and NIHSS, National Institutes of Health Stroke
Scale.
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